The FDA announced a revision to existing system which governs the labeling drug makers must include with prescriptions to explain the risk and benefits of their medications during pregnancy and breastfeeding.
Japan-based Otsuka announced the forthcoming acquisition of U.S.-based Avanir in a deal worth $3.5 billion. Otsuka expects the move to broaden their existing portfolio of neurological drugs and broaden their foothold in the U.S. market, Reuters reports.
Scientific research at three major Russian research centers in St. Petersburg, Novosibirsk, and Moscow have HIV vaccines in development which are ready to enter into clinical trial, the Russian News Agency Reports.
Ralph Neas, president of the Generic Pharmaceutical Association (GPhA) issued a statement in response to Washtington’s recent probe into the rise of generic drug costs and proposed generic drug legislation.
The FDA announced its approval of Hysingla ER (hydrocodone bitartrate), an extended release analgesic meant for long-term treatment of severe pain. Purdue Pharma will release the drug with language outlining its abuse-deterrent properties, which is consistent with the FDA’s 2013 guidance.
Three years into Prime Minister David Cameron’s ten-year strategy for boosting life sciences in the U.K., the British government is working with pharma industry leaders to speed patient access to newly approved drugs.
New research published this week by Scripps Research Institute (TSRI) gives scientists new insight into the mechanics of ZMapp, an experimental Ebola treatment, which might direct and influence future Ebola drug discoveries.